Novan’s shares in meltdown following "discordant" PhIII studies of a new acne drug
Officially, Novan $NOVN put out some mixed data from two Phase III studies of their lead drug for acne, with one success and one failure. But even the positive data from one trial failed to stand out from the control arm in a major way, putting this company under a cloud.
Its stock plunged 80% this morning.
On the up side, investigators say that SB204 hit all three co-primary endpoints for NI-AC302, with significant – though far from impressive – results for reducing the number of lesions and acne clearance. Here are the numbers, for both studies:
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.